438050-07-8

Usage

Uses

Used in Pharmaceutical Industry:
(R)-2-Ethylpiperazine dihydrochloride is used as a key intermediate for the synthesis of compounds targeting the 5-HT2 receptor. Its application is primarily for the development of drugs aimed at treating disorders associated with this receptor, such as schizophrenia, anxiety, and depression. The R-configuration of (R)-2-ethylpiperazine dihydrochloride allows for enhanced selectivity and efficacy in modulating the 5-HT2 receptor, leading to improved therapeutic outcomes.
Additionally, (R)-2-ethylpiperazine dihydrochloride serves as a versatile building block for the synthesis of other pharmaceutical compounds. Its unique structure and functional groups enable chemists to create a wide range of molecules with diverse therapeutic applications. This makes it an invaluable asset in the field of medicinal chemistry and drug discovery, contributing to the development of innovative treatments for various diseases and conditions.

Upstream product

• 325145-35-5 (S)-2-ethylpiperazine-1-carboxylic acid tert-butyl ester 
• 393781-70-9 (R)-2-ethylpiperazine-1-carboxylic acid tert-butyl ester 
• 347195-55-5 (R)-1-benzyl-3-ethylpiperazine 

Downstream Products

• 438050-08-9 tert-butyl (3R)-3-ethylpiperazine-1-carboxylate 

Relevant academic research and scientific papers

MORPHOLINOPURINE DERIVATIVES

There is provided a novel compound that inhibits phosphatidylinositol 3-kinase (PI3K) and/or the mammalian target of rapamycin (mTOR) and exhibits anti-tumor activity. The present invention provides a compound represented by the following formula (1) having various substituents that inhibits PI3K and/or mTOR and exhibits anti-tumor activity: wherein R1, R2, R3, R4, Ra, Rb, Rc, and X each have the same meaning as defined in the specification.

5,7-DIAMINOPYRAZOLO`4,3-D!PYRIMIDINES USEFUL IN THE TREATMENT OF HYPERTENSION

This invention relates to compounds of formula (I).

Novel piperazine derivatives

The present invention is a chemical compound of formula (I) or a pharmaceutically acceptable salts, solvates and esters thereof, wherein R1 to R4, A1, A2 m and n are as described in the specification.

NOVEL SULFONYL DERIVATIVES

Sulfonyl derivatives represented by the following general formula (I): Q1-Q2-T1-Q3-SO2-QA and drugs containing the same (wherein Q1 is an optionally substituted, saturated or unsaturated, five- or six-membered cyclic hydrocarbon group, a five- or six-membered heterocyclic group, or the like; Q2 is a single band, oxygen, sulfur, C1-C6 alkylene or the like; QA is optionally substituted arylalkenyl, heteroarylalkenyl or the like; and T1 is carbonyl or the like). These compounds have potent FXa-inhibitory effects and promptly exert satisfactory and persistent antithrombotic effects through oral administration, thus being useful as anticoagulant agents little accompanied with side effects.